Name: Siamycin I
Brand: Biolinks K.K.
SKU: BLK-0900

For Research Use Only. Not for human or veterinary use.

Siamycin I (CAS: 164802-68-0) Product ID: BLK-0900 CAS 164802-68-0 Mechanism HIV fusion inhibitor Primary Target HIV-1 gp160; Lipid II; Histidine kinase FsrC; Histidine kinase VanS Pathway Viral membrane fusion pathway; Peptidoglycan biosynthesis; Two-component signaling pathway
Structure
CAS	164802-68-0
Molecular Formula	C97H131N23O26S4
Molecular Weight	2163.52
Price	1mg: USD 190.00 / 5mg: - / 25mg: -
Storage	-20°C
Solubility	1mg/ml ethanol, methanol, DMSO
Purity	>95% [View LC/UV Data]
NMR Data	1H NMR (CD3OD, 500 MHz) [View]
Source Organism	Streptomyces sp.
Summary	Siamycin I is a 21-residue lasso peptide that inhibits HIV fusion and targets lipid II.
Details	Siamycin I is a 21-residue tricyclic lasso peptide (RiPP) derived from Streptomyces that inhibits HIV-1 and HIV-2 fusion and viral replication through noncovalent interaction with the gp160 envelope glycoprotein, with resistance mapping to envelope mutations. Structural studies established a compact, amphipathic, wedge-shaped conformation stabilized by disulfide bonds and an N-terminal macrolactam linkage. Beyond antiviral activity, siamycin I directly binds lipid II at the Gram-positive cell surface, compromising peptidoglycan biosynthesis and activating the liaI stress response. Additionally, it inhibits the histidine kinases FsrC and VanS, abolishing enterococcal virulence and restoring vancomycin susceptibility in resistant pathogens. These mechanistic findings define siamycin I as a multifunctional lasso peptide targeting viral envelope-mediated fusion and essential bacterial cell-wall signaling pathways.
Browse Related	Mechanism HIV fusion inhibitor Open full index Primary Target HIV-1 gp160; Lipid II; Histidine kinase FsrC; Histidine kinase VanS Open full index Pathway Viral membrane fusion pathway; Peptidoglycan biosynthesis; Two-component signaling pathway Open full index Chemical Class Lasso peptide (RiPP) Open full index
Mechanism	HIV fusion inhibitor
Primary Target	HIV-1 gp160; Lipid II; Histidine kinase FsrC; Histidine kinase VanS
Pathway	Viral membrane fusion pathway; Peptidoglycan biosynthesis; Two-component signaling pathway
Chemical Class	Lasso peptide (RiPP)
Discovery Year	1994
Keywords	lasso peptide ribosomally synthesized and post-translationally modified peptide hiv fusion inhibitor lipid ii binder cell wall biosynthesis inhibitor histidine kinase inhibitor anti-virulence peptide natural product research tool
References	Frèchet et al., Biochemistry, 1994 (solution structure; amphipathic lasso peptide) DOI: 10.1007/BF00211754 Romeo et al., Antimicrob Agents Chemother, 1996 (HIV fusion inhibition; gp160 resistance mapping) DOI: 10.1128/AAC.40.1.133 Hegemann et al., ACS Chem Biol, 2019 (lipid II targeting; cell wall biosynthesis inhibition) DOI: 10.1021/acschembio.9b00157 Berger et al., iScience, 2025 (histidine kinase FsrC/VanS inhibition; anti-virulence; vancomycin restoration) DOI: 10.1016/j.isci.2025.111922
Request pricing, availability, or bulk supply information for this compound. Get a Quote General Inquiry
Documents 📄 Safety Data Sheet (SDS) – Download PDF 📄 Product Specification Sheet (PDS) – Download PDF 🧪 Certificate of Manufacture (CofM) – Download HTML
← Back to Catalog
Representative LC/UV Data HPLC Conditions (typical): Column: C18 Mobile phase: 5–100% ACN / H2O (0.05% H3PO4), linear gradient 20 min Flow rate: 0.2 mL/min Detection: 210 nm Representative analytical data. Actual batch data may vary.
Representative NMR Data 1H NMR (CD3OD, 500 MHz) Representative spectral data. Actual batch data may vary.

Siamycin I (CAS: 164802-68-0)